Taysha’s fully funded TSHA-102 launch opportunity offers substantial asymmetric upside, but valuation remains hostage to pivotal data, manufacturing validation, and regulatory execution.
Overview
Taysha Gene Therapies is a pre-commercial AAV gene-therapy developer whose value is concentrated in TSHA-102, an intrathecal scAAV9 therapy designed to restore MECP2 expression in Rett syndrome. The opportunity is clinically meaningful: REVEAL Part A reported a 100% response rate at 12 months and an average gain or regain of 26 functional skills across 12 patients, while no treatment-related serious adverse events or dose-limiting toxicities were reported across 33 treated patients as of August 2026. **The company is funded through the second half of 2028**, following a $230.0 million June offering that left $455.4 million of cash at June 30, 2026. Q2 revenue was $0, R&D was $38.6 million, G&A was $12.1 million, and GAAP net loss was $46.6 million. The principal catalysts are PPQ manufacturing completion in Q4 2026 and six-month REVEAL data plus FDA feedback in H1 2027. **Valuation is favorable but binary**: the DCF implies $9.50 per share versus a $6.37 reference price, while the probability-weighted 2031 scenario value is $11.97. Risks include manufacturing comparability, regulatory design, AAV9 safety, Neurogene competition, payer adoption, and future dilution.